> top > docs > PubMed:20299331 > spans > 129-707 > annotations

PubMed:20299331 / 129-707 JSONTXT

Annnotations TAB JSON ListView MergeView

Allie

Id Subject Object Predicate Lexical cue
SS1_20299331_2_0 8-34 expanded denotes mineralocorticoid receptor
SS2_20299331_2_0 36-38 abbr denotes MR
SS1_20299331_3_0 241-255 expanded denotes embryonic stem
SS2_20299331_3_0 257-259 abbr denotes ES
AE1_20299331_2_0 SS1_20299331_2_0 SS2_20299331_2_0 abbreviatedTo mineralocorticoid receptor,MR
AE1_20299331_3_0 SS1_20299331_3_0 SS2_20299331_3_0 abbreviatedTo embryonic stem,ES

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 404-418 HP_0001638 denotes cardiomyopathy
T2 420-431 HP_0001649 denotes tachycardia
T3 437-447 HP_0011675 denotes arrhythmia

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 0-578 OBJECTIVE denotes Cardiac mineralocorticoid receptor (MR) activation triggers adverse cardiovascular events that could be efficiently prevented by mineralocorticoid antagonists. To gain insights into the pathophysiological role of MR function, we established embryonic stem (ES) cell lines from blastocysts of transgenic mice overexpressing the human MR driven by its proximal P1 or distal P2 promoter and presenting with cardiomyopathy, tachycardia, and arrhythmia. Cardiomyocyte differentiation allowed us to investigate the molecular mechanisms contributing to MR-mediated cardiac dysfunction.